基于“因势利导”思想对中药灌肠治疗慢性肾脏病的用药探讨
Exploring the Use of Chinese Herbal Enema for the Treatment of Chronic Kidney Disease Based on the Concept of “Treatment Guidance According to the General Trend”
DOI: 10.12677/acm.2026.161348, PDF,   
作者: 杨善铎：黑龙江中医药大学研究生院，黑龙江 哈尔滨；代丽娟*：黑龙江中医药大学附属第一医院肾病二科，黑龙江 哈尔滨；黑龙江省中医药科学院，黑龙江 哈尔滨
关键词: 因势利导；慢性肾脏病；中药灌肠；肠–肾轴；Treatment Guidance According to the General Trend； Chronic Kidney Disease； Chinese Herbal Enema； Gut-Kidney Axis
摘要: 因势利导思想最早来源于中国古代哲学，《黄帝内经》最早将其引入到中医学中，并有着丰富的内涵。慢性肾脏病在我国呈逐年增加的趋势，使国家面临着巨大的医疗经济负担。中药灌肠最早可追溯到《伤寒论》中的蜜煎导法，现在广泛用于临床多种疾病的治疗中，肠肾轴的提出也为中药灌肠提供了更多的现代医学证据。文章将从因势利导思想出发结合传统医学和肠肾轴对中药灌肠治疗慢性肾脏病的用药进行探讨，并基于脏腑气机、邪正盛衰、病邪性质、体质之势进行分析，以期为临床中药灌肠疗法治疗慢性肾脏病用药提供新思路。
Abstract: The idea of treatment guidance according to the general trend originated from ancient Chinese philosophy. The Yellow Emperor’s Inner Canon was first introduced into traditional Chinese medicine and has rich connotations. Chronic kidney disease is increasing year by year in China, posing a huge medical and economic burden on the country. Chinese herbal enema can be traced back to the honey decoction method in the Treatise on Cold Damage, and is now widely used in the treatment of various diseases in clinical practice. The proposal of the gut kidney axis also provides more modern medical evidence for Chinese herbal enema. The article will explore the use of Chinese herbal enema in the treatment of chronic kidney disease based on the idea of treatment guidance according to the general trend and combining it with traditional medicine and the gut kidney axis. It will analyze the principles based on the organ qi mechanism, the rise and fall of pathogenic factors, the nature of pathogenic factors, and the trend of physical constitution. The aim is to provide new ideas for the use of Chinese herbal enema therapy in the treatment of chronic kidney disease in clinical practice.
文章引用：杨善铎, 代丽娟. 基于“因势利导”思想对中药灌肠治疗慢性肾脏病的用药探讨[J]. 临床医学进展, 2026, 16(1): 2866-2874. https://doi.org/10.12677/acm.2026.161348

参考文献

[1] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组, 高翔, 梅长林. 慢性肾脏病筛查诊断及防治指南[J]. 中国实用内科杂志, 2017, 37(1): 28-34.
[2] Bikbov, B., Purcell, C.A., Levey, A.S., Smith, M., Abdoli, A., Abebe, M., et al. (2020) Global, Regional, and National Burden of Chronic Kidney Disease, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet, 395, 709-733. [Google Scholar] [CrossRef] [PubMed]
[3] Jha, V., Wang, A.Y. and Wang, H. (2012) The Impact of CKD Identification in Large Countries: The Burden of Illness. Nephrology Dialysis Transplantation, 27, iii32-iii38. [Google Scholar] [CrossRef] [PubMed]
[4] 许正锦, 邱明山, 郭宇英, 等. 慢性肾脏病中医病因病机探讨[J]. 辽宁中医药大学学报, 2011, 13(10): 137-139.
[5] 邹燕勤, 易岚. 治肾学术思想与临证思辨[J]. 江苏中医药, 2017, 49(2): 1-6.
[6] 郭旸, 饶向荣, 尹德海, 等. 戴希文教授治疗肾脏病学术思想和临床经验[J]. 中国中西医结合杂志, 2024, 44(8): 993-996.
[7] 李莲花, 张佩青. 张琪教授从脾胃治疗慢性肾脏病的经验[J]. 中国中西医结合肾病杂志, 2016, 17(5): 386-387.
[8] 沈金峰, 胡芳, 晏子友, 等. 皮持衡治疗慢性肾脏病经验总结[J]. 辽宁中医杂志, 2020, 47(2): 53-55.
[9] 武士锋, 王自敏. 王自敏从“瘀”论治慢性肾脏病经验[J]. 上海中医药杂志, 2010, 44(6): 19-20, 25.
[10] 赵怡蕊, 陈磊, 侯燕琳, 等. 张大宁教授应用“升清降浊”法治疗肾脏病的“理”与“效” [J]. 世界中医药, 2013, 8(9): 1006-1009.
[11] 冯文涛, 韩耀国, 孙芳园, 等. 中药灌肠法的临床应用研究进展[J]. 世界中西医结合杂志, 2020, 15(8): 1565-1568.
[12] Meijers, B.K.I. and Evenepoel, P. (2011) The Gut-Kidney Axis: Indoxyl Sulfate, P-Cresyl Sulfate and CKD Progression. Nephrology Dialysis Transplantation, 26, 759-761. [Google Scholar] [CrossRef] [PubMed]
[13] Rysz, J., Franczyk, B., Ławiński, J., Olszewski, R., Ciałkowska-Rysz, A. and Gluba-Brzózka, A. (2021) The Impact of CKD on Uremic Toxins and Gut Microbiota. Toxins, 13, Article 252. [Google Scholar] [CrossRef] [PubMed]
[14] 韩文贝, 刘莹露, 万毅刚, 等. 慢性肾脏病肠道菌群失调的病理机制、治疗策略及中药的干预作用[J]. 中国中药杂志, 2017, 42(13): 2425-2432.
[15] Cao, C., Zhu, H., Yao, Y. and Zeng, R. (2022) Gut Dysbiosis and Kidney Diseases. Frontiers in Medicine, 9, Article 829349. [Google Scholar] [CrossRef] [PubMed]
[16] Feng, Z., Wang, T., Dong, S., Jiang, H., Zhang, J., Raza, H.K., et al. (2021) Association between Gut Dysbiosis and Chronic Kidney Disease: A Narrative Review of the Literature. Journal of International Medical Research, 49. [Google Scholar] [CrossRef] [PubMed]
[17] Andersen, K., Kesper, M.S., Marschner, J.A., Konrad, L., Ryu, M., Kumar VR, S., et al. (2016) Intestinal Dysbiosis, Barrier Dysfunction, and Bacterial Translocation Account for CKD-Related Systemic Inflammation. Journal of the American Society of Nephrology, 28, 76-83. [Google Scholar] [CrossRef] [PubMed]
[18] Hu, X., Ouyang, S., Xie, Y., Gong, Z. and Du, J. (2020) Characterizing the Gut Microbiota in Patients with Chronic Kidney Disease. Postgraduate Medicine, 132, 495-505. [Google Scholar] [CrossRef] [PubMed]
[19] Kim, J.E., Kim, H., Park, J.I., Cho, H., Kwak, M., Kim, B., et al. (2020) The Association between Gut Microbiota and Uremia of Chronic Kidney Disease. Microorganisms, 8, Article 907. [Google Scholar] [CrossRef] [PubMed]
[20] Liu, W., Huang, J., Liu, T., Hu, Y., Shi, K., Zhou, Y., et al. (2023) Changes in Gut Microbial Community Upon Chronic Kidney Disease. PLOS ONE, 18, e0283389. [Google Scholar] [CrossRef] [PubMed]
[21] Kim, M., Yang, J. and Jo, S. (2021) Intestinal Microbiota and Kidney Diseases. Kidney Research and Clinical Practice, 40, 335-343. [Google Scholar] [CrossRef] [PubMed]
[22] Chi, M., Ma, K., Wang, J., Ding, Z., Li, Y., Zhu, S., et al. (2021) The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease. Journal of Immunology Research, 2021, Article ID: 5516035. [Google Scholar] [CrossRef] [PubMed]
[23] König, J., Wells, J., Cani, P.D., García-Ródenas, C.L., MacDonald, T., Mercenier, A., et al. (2016) Human Intestinal Barrier Function in Health and Disease. Clinical and Translational Gastroenterology, 7, e196. [Google Scholar] [CrossRef] [PubMed]
[24] Shen, L., Su, L. and Turner, J.R. (2009) Mechanisms and Functional Implications of Intestinal Barrier Defects. Digestive Diseases, 27, 443-449. [Google Scholar] [CrossRef] [PubMed]
[25] Farhadi, A., Banan, A., Fields, J. and Keshavarzian, A. (2003) Intestinal Barrier: An Interface between Health and Disease. Journal of Gastroenterology and Hepatology, 18, 479-497. [Google Scholar] [CrossRef] [PubMed]
[26] Vaziri, N.D., Yuan, J. and Norris, K. (2012) Role of Urea in Intestinal Barrier Dysfunction and Disruption of Epithelial Tight Junction in Chronic Kidney Disease. American Journal of Nephrology, 37, 1-6. [Google Scholar] [CrossRef] [PubMed]
[27] Wang, F., Zhang, P., Jiang, H. and Cheng, S. (2012) Gut Bacterial Translocation Contributes to Microinflammation in Experimental Uremia. Digestive Diseases and Sciences, 57, 2856-2862. [Google Scholar] [CrossRef] [PubMed]
[28] Shi, K., Wang, F., Jiang, H., Liu, H., Wei, M., Wang, Z., et al. (2014) Gut Bacterial Translocation May Aggravate Microinflammation in Hemodialysis Patients. Digestive Diseases and Sciences, 59, 2109-2117. [Google Scholar] [CrossRef] [PubMed]
[29] Vaziri, N.D. (2014) Gut Microbial Translocation in the Pathogenesis of Systemic Inflammation in Patients with End-Stage Renal Disease. Digestive Diseases and Sciences, 59, 2020-2022. [Google Scholar] [CrossRef] [PubMed]
[30] 崔移明, 彭贵军, 胡心, 等. 基于数据挖掘及网络药理学探讨中药灌肠治疗慢性肾疾病的核心中药及机制[J]. 西安交通大学学报(医学版), 2022, 43(2): 286-296.
[31] Zhang, Z., Li, M., Liu, D., Chen, H., Chen, D., Tan, N., et al. (2018) Rhubarb Protect against Tubulointerstitial Fibrosis by Inhibiting TGF-β/Smad Pathway and Improving Abnormal Metabolome in Chronic Kidney Disease. Frontiers in Pharmacology, 9, Article 1029. [Google Scholar] [CrossRef] [PubMed]
[32] Zhang, F., Wu, R., Liu, Y., Dai, S., Xue, X., Li, Y., et al. (2023) Nephroprotective and Nephrotoxic Effects of Rhubarb and Their Molecular Mechanisms. Biomedicine & Pharmacotherapy, 160, Article ID: 114297. [Google Scholar] [CrossRef] [PubMed]
[33] 张晗, 张磊, 刘洋. 龙骨、牡蛎化学成分、药理作用比较研究[J]. 中国中药杂志, 2011, 36(13): 1839-1840.
[34] 李静, 王利, 彭文, 等. 黄芪治疗肾脏疾病的研究进展[J]. 中南药学, 2017, 15(1): 85-87.
[35] 谢永祥, 龙春莉, 钟建, 等. 慢性肾脏病分期辨治的探讨[J]. 现代中西医结合杂志, 2011, 20(17): 2154-2155.
[36] 周丽丽, 张宁. 中药灌肠治疗慢性肾衰竭时机与疗效的探讨[J]. 中华中医药杂志, 2009, 24(8): 1074-1076.
[37] 张妍妍, 韦建华, 卢澄生, 等. 桃仁化学成分、药理作用及质量标志物的预测分析[J]. 中华中医药学刊, 2022, 40(1): 234-241.
[38] 王佐梅, 肖洪彬, 李雪莹, 等. 中药红花的药理作用及临床应用研究进展[J]. 中华中医药杂志, 2021, 36(11): 6608-6611.
[39] 王宇阳, 马放, 占永立. 基于“浊毒”理论论治慢性肾脏病[J]. 中医杂志, 2019, 60(16): 1374-1377.
[40] 张博, 朱建光. 浅析大黄在《伤寒杂病论》中的应用及其现代药理机制[J]. 中医学报, 2017, 32(5): 766-769.
[41] 陈宗俊, 王诗尧, 史银春, 等. 吕仁和从内风论治慢性肾脏病药对浅析[J]. 北京中医药, 2021, 40(6): 590-594.
[42] 谭强来, 陆馨敏, 吴兰兰, 等. 牡蛎多糖缓解体力疲劳及其对力竭小鼠肠道菌群的影响[J]. 中国微生态学杂志, 2024, 36(4): 390-400.
[43] 于敏, 张波, 王汉斌, 等. 从中医体质学说谈慢性肾脏病的发生与预防[J]. 中华中医药学刊, 2009, 27(9): 1825-1827.
[44] 张蕾, 刘旭生. 195例慢性肾脏病3-5期中医证候分布规律探析[J]. 辽宁中医杂志, 2012, 39(6): 980-983.
[45] 孙伟. 论"湿邪"在慢性肾脏病中的作用和辨治[J]. 中国中西医结合肾病杂志, 2023, 24(6): 471-473.
[46] 栾仲秋, 张忠绅, 张慧杰. 基于肠道菌群及脂质代谢探讨慢性肾脏病微炎症状态“湿瘀互结”的病机内涵[J]. 中医学报, 2024, 39(5): 919-923.
[47] 王禹霖, 刘梦超, 郑冰洁, 等. 名中医张炳厚从瘀论治慢性肾脏病经验撷英[J]. 陕西中医, 2023, 44(11): 1602-1605.
[48] 张晓楠, 宋立群. 活血化瘀法在肾脏病中的应用[J]. 中医药学报, 2008(1): 44-45.
[49] 刘光珍, 赵文景, 魏连波, 等. 从瘀论治慢性肾脏病的思路与方法[J]. 中国中西医结合肾病杂志, 2021, 22(7): 656-658.
[50] 张保春, 赵进喜, 王世东, 等. 因势利导, 给邪以出路, 治病求本, 辨证以求效[J]. 环球中医药, 2020, 13(11): 1878-1881.

为你推荐